Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CNTY-101
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Century Announces Phase 1/2 Trial of iNK Cell Therapy CNTY-101 in Autoimmune Diseases
Details : CNTY-101, targeting CD19 for relapsed, refractory B-cell lymphoma, is an allogeneic, iPSC-derived CAR-iNK cell therapy, intended for moderate to severe systemic lupus erythematosus.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
January 21, 2025
Lead Product(s) : CNTY-101
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CNTY-101
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Bain Capital Life Sciences
Deal Size : $60.0 million
Deal Type : Private Placement
Century Therapeutics Expands Autoimmune Pipeline Supported by $60M and Clade Acquisition
Details : Century intends to use the net proceeds to support the expansion of CNTY-101, a CD19-targeting iNK cell therapy, currently being evaluated in a clinical trial in B-cell malignancies.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
April 11, 2024
Lead Product(s) : CNTY-101
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Bain Capital Life Sciences
Deal Size : $60.0 million
Deal Type : Private Placement
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Clade Therapeutics
Deal Size : $45.0 million
Deal Type : Acquisition
Century Therapeutics Strengthens Position in Autoimmune with Pipeline Expansion
Details : Acquisition of Clade Therapeutics strengthens Century’s position as a leader in allogeneic, iPSC-derived cell therapy through enhancement of pipeline and next generation Allo-EvasionTM platform.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $45.0 million
April 11, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Clade Therapeutics
Deal Size : $45.0 million
Deal Type : Acquisition
Lead Product(s) : CNTY-101
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases
Details : CNTY-101 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lupus Erythematosus, Systemic.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
February 12, 2024
Lead Product(s) : CNTY-101
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CNTY-101
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CNTY-101, targeting CD19 for relapsed, refractory B-cell lymphoma, is an allogeneic, iPSC-derived CAR-iNK cell therapy, administered via Intravenous Infusion, intended for moderate to severe systemic lupus erythematosus.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
December 06, 2023
Lead Product(s) : CNTY-101
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Study Phase : Discovery
Recipient : Fujifilm Cellular Dynamics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : The agreement aims for the development and commercialization of cell therapies derived from iPSCs for the treatment of autoimmune and inflammatory diseases, including type 1 diabetes, multiple sclerosis, lupus, and rheumatoid arthritis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 09, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Discovery
Recipient : Fujifilm Cellular Dynamics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : CNTY-101 is an investigational off-the-shelf cancer immunotherapy product candidate that utilizes iPSC-derived NK cells with a CD19-directed CAR and designed to overcome the three major pathways of host versus graft rejection - CD8+ T cells, CD4+ T cells...
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
February 08, 2023
Century Therapeutics to Present at the SITC 37th Annual Meeting
Details : CNTY-101, targeting CD19 for relapsed, refractory B-cell lymphoma, is an allogeneic, iPSC-derived CAR-iNK cell therapy that has been engineered to express CD19 CAR, soluble IL-15, and an EGFR safety switch.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
October 05, 2022
Details : CNTY-101 is the first allogeneic cell product candidate with six genetic modifications incorporated using sequential rounds of CRISPR-mediated homologous recombination and repair that has received IND clearance by the FDA.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
August 25, 2022
Lead Product(s) : CNTY-102
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Century Therapeutics to Present at the ASGCT 25th Annual Meeting
Details : CNTY-102 simultaneously target CD19 and CD79b designed to increase depth and durability of response by eliminating effect of CD19 antigen loss that has been observed as factor limiting treatment durability while targeting CD79b.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
May 02, 2022
Lead Product(s) : CNTY-102
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable